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Introduction: Ireland currently has the highest reported rate in Europe of vancomycin-resistant
Enterococcus (VRE) isolated from the bloodstream, but data regarding the prevalence of VRE
endocarditis remain scarce. Treatment options for Enterococcus-mediated endocarditis are
limited, and therefore daptomycin is commonly used off licence in this setting.
Case presentation: A 60-year-old male with end-stage kidney disease (ESKD) presented with
VRE bacteraemia secondary to a gangrenous right foot colonized with vancomycin-resistant
Enterococcus faecium. Aortic valve endocarditis was confirmed using transoesophageal
echocardiography. Treatment was commenced with linezolid and subsequently modified to
combination therapy with daptomycin and rifampicin. High-dose daptomycin therapy was
employed unsuccessfully and, after 20 days of therapy, daptomycin resistance emerged, which
proved fatal.
Conclusion: The case was ethically challenging and involved a refusal of amputation and,
ultimately, any form of treatment by the patient. In summary, however, daptomycin-resistant VRE
bacteraemia complicated by recalcitrant daptomycin-resistant VRE endocarditis proved fatal for
this patient. Further evaluation of the efficacy and safety of high-dose daptomycin for the
treatment of VRE infective endocarditis is needed.
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Introduction
Enterococci are Gram-positive organisms that form part of
the commensal gut flora. A common nosocomial pathogen
resistant to many antimicrobials, enterococci can reside
and survive in the clinical environment for prolonged
periods with an associated risk of contaminating healthcare
workers and the potential for cross-transmission to
patients (Biedenbach et al., 2004). Enterococci are the
second most common nosocomial bloodstream pathogen
isolated in the USA with the prevalence of vancomycin-
resistant Enterococcus (VRE) in intensive care units
currently exceeding 30 % (Wisplinghoff et al., 2004).
Enterococcus faecalis and Enterococcus faecium are the pre-
dominant pathogens associated with VRE infections
(Carmeli et al., 2002). Ireland has the highest proportion
of VRE bloodstream isolates in Europe, as reported to
the European Centre for Disease Prevention and Control.
In 2013, 176 VRE were identified among 408 E. faecium
isolates from bloodstream infections in Ireland (43.1 %).
VRE results in significant increases in length of hospital
admission and mortality (DiazGranados et al., 2005).
For patients agedj60 years, enterococci account for up to
10 % of cases of native valve infective endocarditis, rising
to almost 20 % in those w60 years. In prosthetic valve
endocarditis, 5–10 % of cases that occur in the first
60 days post-operatively and up to 15 % of cases occurring
after 60 days are secondary to enterococcal infection
(Mylonakis and Calderwood, 2001). The first case of
VRE infective endocarditis was reported in 1996 (Bishara
et al., 1999), but subsequent reports in the literature have
been rare (Forrest et al., 2011). A study involving a
review of 107 cases of enterococcal endocarditis noted no
cases secondary to vancomycin resistance (McDonald
Abbreviations: ESKD, end-stage kidney disease; i.v., intravenous; VRE,
vancomycin-resistant Enterococcus.
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et al., 2005). Haemodialysis patients and renal transplant
recipients are at relatively high risk of VRE infective endo-
carditis (Humphreys et al., 2004), and rates of intestinal
VRE colonization have been shown to be higher in these
groups than in other patient populations (Patel et al., 2001).
There are limited effective antimicrobial treatment options
for VRE infections including infective endocarditis. Dapto-
mycin is a concentration-dependent bactericidal lipopep-
tide antibiotic, licensed in the Republic of Ireland for the
treatment of skin and soft tissue infections. It is also
licensed for use in the management of Staphylococcus
aureus bacteraemia, including right-sided endocarditis,
at doses of 4 and 6 mg (kg body weight)21, respectively
(Boucher and Sakoulas, 2007). Dose adjustment is required
for patients with renal impairment. It is used off label in
Ireland to treat patients infected with VRE. It is excreted
renally (Hawkey, 2008) and is rapidly bactericidal
(Mascio et al., 2007), and had demonstrated in vitro con-
centration-dependent killing with a half-life of 8–9 h
(LaPlante and Rybak, 2004). The drug acts on the cell
membrane causing membrane depolarization and also
inhibits the synthesis of lipoteichoic acid, which is necess-
ary for cell wall synthesis (Enoch et al., 2007). Daptomycin
displays in vitro activity against w90 % of Enterococcus
spp., including those resistant to other antibiotics, such
as vancomycin, linezolid and quinupristin-dalfopristin
(Sader and Jones, 2009). Thickening of the cell wall
associated with vancomycin intermediate-susceptible
S. aureus isolates has been shown to decrease susceptibility
to daptomycin and, while an exact resistance mechanism in
enterococci has not yet been determined, a similar
mechanism secondary to reduced daptomycin diffusion
through a thickened enterococcal cell wall has been
proposed (Cui et al., 2006; Kelley et al., 2011).
To the best of our knowledge, this is the first report of dap-
tomycin-resistant VRE aortic valve infective endocarditis
complicated by end-stage kidney disease (ESKD) in Ireland
and one of only nine reports of daptomycin-resistant infec-
tive endocarditis globally based on a Pubmed search com-
pleted in July 2015. In that search, no reports of such
endocarditis complicated by kidney disease could be found.
Case report
The right big toe of a 60-year-old Irish male with ESKD sec-
ondary to diabetic nephropathy on haemodialysis became
gangrenous secondary to peripheral vascular disease, and
he underwent a toe amputation in May 2010. Samples
taken from the wound were determined to be positive for
VRE (E. faecium) and a surveillance rectal swab detected
that the patient was VRE colonized. He was commenced
on a 5-week course of intravenous (i.v.) linezolid 600 mg
twice daily followed by 7 days of oral linezolid 600 mg
twice daily with limited resolution. A right mid-foot ampu-
tation was performed in September 2010 followed by
wound debridement in October 2010. The history of this
infected foot dated back to 2008 when he had his first
episode of cellulitis requiring antimicrobials. With each
progressively worsening foot infection, the patient was
very reluctant to undergo any surgical procedure to
remove the nidus of infection, necessitating prolonged anti-
microbial exposure. Between October 2009 and January
2010, a 16-week admission occurred for a Klebsiella pnue-
moniae and Candida albicans continuous ambulatory perito-
neal dialysis-associated peritonitis requiring a protracted
prescription of broad-spectrum bacterial and fungal cover.
Ultimately, the patient was commenced on haemodialysis.
On 15 July 2011, he was admitted from the dialysis unit with
sepsis. Blood samples were taken from the dialysis permacath,
whichwere positive forVRE. Laboratory testing again demon-
strated the presence of E. faecium, demonstrating the same
antibiogram as the earlier VRE cultured in 2010. He was com-
menced on i.v. linezolid 600 mg twice daily. A transthoracic
echocardiogram was performed, which did not show any
vegetations suspicious for infective endocarditis. Consecutive
blood cultures, 48 h apart, demonstrated evidence of continu-
ous VRE bacteraemia. Sterility of blood was achieved for
22 days until a set of blood cultures taken in early August
2011 again yielded VRE. A transoesophageal echocardiogram
identified vegetations on the aortic valve. A decisionwasmade
to switch from linezolid 600 mg twice daily to daptomycin
6 mg kg21 i.v. administered following dialysis sessions.
Seven days later, with blood cultures still VRE positive, rifam-
picin 600 mg twice daily i.v. was added for additional synergis-
tic bactericidal activity as the patient also had an ongoing
active foot infection, for which source control had not been
achieved. An interdialytic daptomycin dosing regimen was
commencedwithdaptomycin at8, 8 and10 mgkg21 adminis-
tered post-dialysis at 48, 48 and 72 h, respectively (following
consultation with the suppliers of the antimicrobial agents
and a review of available literature) (Salama et al., 2009).
The patient consistently declined amputation of his right leg
during his final admission. Following 17 days of therapy
(29 August 2011), we noted daptomycin resistance (MIC
w8 mg l21) during routine in-house susceptibility testing.
In early September 2011, with worsening necrosis and
gangrene of his right leg, confirmed aortic valve endocarditis,
unresolving VRE bacteraemia and rising C-reactive protein,
togetherwith refusal to consent to a right leg amputation, the
patient undertook his own discharge from hospital with
rifampicin 600 mg twice daily per os and daptomycin 6 mg
kg21 i.v. once daily to be administered intravenously in the
community. He continued to deteriorate with persistent
VRE bacteraemia. Dialysis was subsequently withdrawn fol-
lowing consultation with the patient and his family, as there
was consensus that, given ongoing sepsis from multiple
sources, the patient was too unwell to continue with haemo-
dialysis. Antimicrobial therapy also ceased at this time. Pal-
liative care services reviewed the patient and he was admitted
to a local hospice where he died 2 weeks later.
Discussion
Patients undergoing outpatient haemodialysis are at high
risk of VRE acquisition due to repeated close contact
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between patients in the dialysis unit, repeated exposure of
patients to antimicrobials including vancomycin for treat-
ment of dialysis line infections (at least in Ireland), shared
transport to dialysis units and frequent hospital admissions
(Kee et al., 2012). The reliance on central catheters in the
dialysis population is thought to be a key factor contribut-
ing to the rise of resistant enterococcal isolates (Boucher
et al., 2009). To place this case in context, at the time of
writing, the University Hospital Limerick dialysis unit is
attended by 67 patients of whom 37 are VRE positive.
A further 78 attend a satellite dialysis unit in the nearby
city centre of whom 11 are known to be VRE positive.
Mortality rates in patients with VRE bloodstream infec-
tions are high, ranging between 20 and 46 % (Han et al.,
2009; McKinnell et al., 2011; Twilla et al., 2012), and bac-
terial endocarditis in dialysis patients is associated with
poor prognosis (Leither et al., 2013). Surgical management
of VRE infective endocarditis is rarely employed, as most
patients have significant co-morbidities that would prohi-
bit such invasive intervention (Salgado and Farr, 2003).
As a consequence, medical management is the preferred
treatment approach. The use of daptomycin as monother-
apy for the treatment of VRE endocarditis is not rec-
ommended due to increased risk of resistance (Linden,
2007; Schulte et al., 2008). Various mechanisms for enter-
ococcal daptomycin resistance have been described includ-
ing altered cell membrane composition, altered ability of
daptomycin to depolarize the cell (Steed et al., 2011) and
the risk of gene transfer of daptomycin-resistant determi-
nants (Kelesidis et al., 2011; Diaz et al., 2014). Concern
has also been raised as to whether a tendency to provide
empiric VRE cover to at-risk patients with daptomycin
and linezolid, while awaiting final culture results, may
also be contributing to the development of resistance sec-
ondary to overuse (Short et al., 2014).
A published analysis of infective endocarditis cases warned
that daptomycin monotherapy for enterococcal infective
endocarditis could not be advocated and recommended
combination therapy of daptomycin with another antimi-
crobial such as rifampicin, gentamicin, linezolid or a
b-lactam for treatment of VRE endocarditis (Cero´n et al.,
2014). Similarly, synergistic therapy with daptomycin and
rifampicin has been advocated (Leclercq et al., 1991).
However, the addition of rifampicin 600 mg twice daily
per os proved ineffective in our patient.
The appropriate dose of daptomycin for VRE infective
endocarditis has not been defined but, as in vivo and
in vitro studies have revealed that using higher doses of
daptomycin increases the degree and speed of bactericidal
activity due to its concentration-dependent pharmacody-
namic mechanism, higher doses than recommended for
S. aureus bacteraemia (6 mg kg21 day21) have been
suggested (Cunha et al., 2007; Hall et al., 2012). At 6 mg
kg21 day21, sterility of blood cultures was not achieved.
The use of daptomycin at higher doses of i8 mg
kg21 day21 (Kullar et al., 2011, 2013) and 14 mg
kg21 day21 (Moise et al., 2009) for the treatment of
infective endocarditis have been demonstrated with no
adverse patient outcomes. Reported cases of daptomycin
resistance have been associated with complicated infections
(e.g. osteomyelitis, medical device infections and endocar-
ditis) at doses ofj6 mg kg21 (Kelesidis et al., 2011). Our
attempt at using intradialytic daptomycin at 8, 8 and
10 mg kg21 post-dialysis at 48, 48 and 72 h, respectively,
also failed. There was no rise in creatinine phosphokinase
levels with daptomycin therapy over 20 days, which was
a positive finding given that rising creatinine phosphokinase
levels can often prohibit the use of daptomycin, particularly
in those with renal impairment.
We are unaware of any randomized controlled trials that
have evaluated the management of VRE infective endocar-
ditis. Linezolid is a bacteriostatic antimicrobial licensed
by the US Food and Drug Administration for treatment
in this setting, but cure rates remain disappointing
(Birmingham et al., 2003; Chuang et al., 2014) and resist-
ance rates of 20 % have been reported (Pogue et al., 2007).
The side-effect profile of linezolid with associated myelo-
suppression, including neutropenia, thromobocytopenia
and anaemia (Hachem et al., 2003) is particularly proble-
matic in the dialysis population. Tigecycline has been
used in combination with other agents for the treatment
of vancomycin-resistant E. faecium infections, but it
achieves low serum levels and reports of its use are scarce
(Florescu et al., 2008; Schutt and Bohm, 2009).
Conclusion
In conclusion, VRE endocarditis is a very uncommon noso-
comial infection but is clinically challenging when it arises,
given the lack of licensed treatment options. In this case, the
same E. faecium isolate persisted from multiple sites despite
antimicrobial therapy, having probably initially been a rectal
colonizer. High-dose daptomycin is generally well tolerated
(and we observed no adverse effects in our patient). Ulti-
mately, without amputation and definitive source control,
this patient was unlikely to clear his VRE bacteraemia,
affording some potential to cure his infective endocarditis.
The ethical issues associated with this case are multi-faceted
and deserve discussion elsewhere. The rapid emergence of
daptomycin resistance following only 20 days of therapy
should heighten the awareness of other centres to this possi-
bility in complicated VRE infections. No linezolid resistance
was observed in this case.
We continue to monitor for resistance in all patients
receiving treatment with daptomycin. The prescription
of daptomycin within our institution remains restricted,
and is permissible following consultation with clinical
microbiology or infectious diseases staff only. To date,
no further cases of VRE infective endocarditis or daptomy-
cin resistance have been identified in our institution.
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